

Quarterly Activities Report and Appendix 4C

HIGHLIGHTS

- Quarterly sales of \$5.4 million, representing an increase of 20%, over the previous quarter and a 15% uplift compared to the prior corresponding period;
- Revenue contribution from all three regions, Australia, EMEA and US, with Australia gaining new business from existing customers, EMEA experiencing a 52% increase in Gastrointestinal (GI) testing and US receiving the first commercial order;
- Second US contract was signed with an integrated healthcare organisation, marking a key milestone in the US commercial expansion. The first shipment of test kits was delivered in September, with testing expected to commence early in Q2 FY2026;
- A third US contract with previous customer experience site signed after the close of the quarter;
- The revised focused sales and marketing strategy combined with improved brand awareness in key geographies is providing strong and growing pipeline of commercial opportunities;
- Continued development of automated, high-throughput solution through the customising of commercially available instruments;
- Strengthening the leadership team with the appointment of Dr Susanne Pederson to the role of Chief Technology Officer (CTO); *and*
- Strong balance sheet with a \$28.2 million cash and term deposit balance on 30 September 2025.


FY2026 has got off to a positive start, with commercial successes across all regions, the Company's financial metrics continue to move in the right direction, and the pipeline development work is well underway.

Operational Update

The Company recorded sales of \$5.4 million (unaudited) for Q1 FY2026 marking its highest quarterly revenue since COVID. This 20% increase from the preceding quarter and 15% increase from prior corresponding period (p.c.p.) is due to commercial successes across all three regions in which the Company operates – US, EMEA and Australia.

Australia gained new business from existing customers, while continuing to experience higher testing rates due to the Southern hemisphere winter respiratory season. EMEA experienced a 52% increase from p.c.p. in GI, and US has received the first commercial order with anticipation of go-live in Q2 FY2026.

Figure 1: GSS Quarterly revenue (A\$m)



Receipts from customers for the quarter were \$5.6 million. Cash receipts were primarily attributable to sales success across all three regions in which the Company operates. Net operating cash outflow for the quarter was \$2.1 million.

Net investing cash outflows of \$0.4 million for the quarter included investments in equipment for placement at customer sites and within the Company's R&D laboratories. Payments of fees to Directors, including the CEO, were \$0.3 million for the quarter and are included in 1.2(e) – staff costs of the Appendix 4C.

As at 30 September 2025, Genetic Signatures held a total cash balance of \$28.2 million, comprising \$10.7 million in cash at bank and \$17.5 million in term deposits. While term deposits are classified as 'other financial assets' in the Annual Report in accordance with accounting standards, they have been included in as 'Cash and cash equivalents' in the Appendix 4C to reflect that the funds are available to the Company for funding future operating activities.

Momentum building in the US

The implementation of the revised go-to-market US strategy is well underway, targeting different market segments and strategically concentrating commercial efforts in four key states. These states represent over half of the total US testing volume, providing a high-yield opportunity to drive growth and deepen customer engagement. This geographic focus enables the team to build and maintain strong, direct relationships with high-value customers, while ensuring efficient and effective allocation of resources.

Early in the quarter, a US contract was signed with a former customer-experience site. This customer is one of the largest nonprofit integrated health care systems in the US. The laboratory will be performing tests on behalf of 56 hospitals. In September the laboratory ordered and received its first shipment of commercial test kits, ahead of go-live in early Q2. The Company is actively engaged in discussions to develop co-marketing initiatives aimed at driving adoption across their extensive network, supporting broader utilisation and market penetration of the *EasyScreen*[™] Gastrointestinal Parasite Detection testing kit.

Following the close of the quarter, Genetic Signatures secured the third signed contract—another customer experience site. The involvement of a respected Key Opinion Leader is expected to enhance market visibility.

The Company showcased the *EasyScreen*[™] Gastrointestinal Parasite Detection Kit at the Southwestern Association of Clinical Microbiology conference held in September 2025. This targeted engagement is part of the Company's broader strategy to build brand awareness and further strengthen the sales pipeline in high-opportunity regions.

To increase brand awareness, a targeted social media campaign was launched during the quarter. This initiative was designed to build broader recognition, ultimately supporting pipeline growth and driving demand through commercial channels. As a result, analytics showed traffic to the Company's website increased, with almost 70% coming from new visitors, with the US outstripping all other geographies.

Unlocking growth opportunities in EMEA

Sales revenue in EMEA for Q1 FY2026 increased by 26.6% on the p.c.p. This improvement in revenue has been attributed to the focus on high-impact geographies with the GI portfolio. GI sales have seen a 52% increase from p.c.p.

The team continues to work with multiple National Health Service (NHS) trusts in the UK, where Genetic Signatures' GI viral, bacterial, and parasite test kits are being used in hospital settings to support infection control and outbreak prevention. These engagements have demonstrated strong clinical value and are contributing to a growing pipeline of opportunities to further expand our footprint in the region. Early feedback from customers is that this solution is 'game changing'!

In September, the Company presented its comprehensive portfolio of molecular testing solutions at the Institute of Biomedical Science Congress in Birmingham, generating considerable interest and engagement from prospective customers, as well as generating some solid leads.

Genetic Signatures continues to assess external distribution partnerships across the EMEA region, with a particular focus on markets where local representation is essential due to linguistic and cultural considerations, and where direct sales operations may not be economically viable. With existing distribution partners beginning to gain traction, the Company is confident that EMEA will deliver increasing contributions in the near to medium term.

Progress on new instruments and software and R&D

During the quarter a collaborative face to face workshop was held between Genetic Signatures, Tecan Group, and Repado to further refine the integration of software with instrumentation. The customised software is designed to enable workflow optimisation, laboratory analytics, inventory management, and field service support.

This collaboration has helped define the detailed scope of work for the second phase of the program, which will focus on the integrated customisation of both hardware and software components.

Genetic Signatures recently completed a comprehensive market assessment, engaging with over 200 industry professionals to gather valuable insights on its integrated hardware and software solution. This

feedback is helping to inform and support the strategic expansion of the Company's **3base**[®] infectious disease syndromic testing menu, which will be launched alongside the new integrated platform.

In conjunction the R&D team remains focused on enhancing workflows for on-market products, with an emphasis on increasing automation and improving the usability of current instrumentation.

Further investments were made in research, development and procurement to reduce risk and to strengthen the supply of key manufacturing components.

Strengthening leadership team

During the quarter, the Company appointed Dr Susanne Pedersen to the role of Chief Technology Officer (CTO). Dr Pedersen has a PhD in molecular biology and over 25 years of experience in the development and commercialisation of molecular *in vitro* diagnostic (IVD) products. Dr Pedersen was a co-founder of Clinical Genomics Pty Ltd where, as Vice President of Science & Innovation, she led the discovery, development and commercialisation of Colvera[™] – Australia's first CLIA-accredited liquid biopsy for colorectal cancer.

Dr Pedersen will have primary responsibility for managing the development of Genetic Signatures' technology and molecular diagnostic products. This will include ongoing initiatives to optimise and streamline Genetic Signature's **3base**[®] technology platform and workflow, the development of new molecular syndromic IVD tests and test products, and overseeing the development of automated, high-throughput systems through the customisation of commercially available instruments.

During the quarter, additional roles were added to the Technology team to support the Chief Technology Officer in advancing the Company's technology development initiatives and to enhance product care for existing customers.

Outlook

Looking ahead, the Company remains focused on strengthening its presence in Australia while accelerating global expansion, with particular emphasis on the United States and the United Kingdom. The Company's solid cash position enables continued, targeted investment in commercial initiatives, while also supporting innovation across assay development, workflow optimisation, instrumentation, and software enhancements.

– END –

Announcement authorised by Genetic Signatures' Board of Directors

For further information, see our website (www.geneticsignatures.com) or contact us:

Allison Rossiter

Chief Executive Officer

allison.rossiter@geneticsignatures.com

T: +61 (0)2 9870 7580

Karl Pechmann

Chief Financial Officer

karl.pechmann@geneticsignatures.com

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base®**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen™* brand. Genetic Signatures' proprietary MDx **3base®** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

GENETIC SIGNATURES LIMITED

ABN

30 095 913 205

Quarter ended ("current quarter")

30 September 2025

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	5,597	5,597
1.2 Payments for		
(a) research and development	(358)	(358)
(b) product manufacturing and operating costs	(2,296)	(2,296)
(c) advertising and marketing	(535)	(535)
(d) leased assets	(104)	(104)
(e) staff costs	(3,763)	(3,763)
(f) administration, corporate and other costs	(1,050)	(1,050)
1.3 Dividends received (see note 3)		
1.4 Interest received	394	394
1.5 Interest and other costs of finance paid	(15)	(15)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(2,130)	(2,130)
2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(392)	(392)

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
2.6 Net cash from / (used in) investing activities	(392)	(392)

3. Cash flows from financing activities		
3.1 Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2 Proceeds from issue of convertible debt securities		
3.3 Proceeds from exercise of options	-	-
3.4 Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5 Proceeds from borrowings	-	-
3.6 Repayment of borrowings	-	-
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Principal element of lease payments	(112)	(112)
3.10 Net cash from / (used in) financing activities	(112)	(112)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	30,873	30,873
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,130)	(2,130)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(392)	(392)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(112)	(112)
4.5	Effect of movement in exchange rates on cash held	(9)	(9)
4.6	Cash and cash equivalents at end of period	28,230	28,230

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	10,730	7,473
5.2	Call deposits	17,500	23,400
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	28,230	30,873

6. Payments to related parties of the entity and their associates

- 6.1 Aggregate amount of payments to related parties and their associates included in item 1
- 6.2 Aggregate amount of payments to related parties and their associates included in item 2

**Current quarter
\$A'000**

274

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

7. Financing facilities

Note: the term "facility" includes all forms of financing arrangements available to the entity.

Add notes as necessary for an understanding of the sources of finance available to the entity.

7.1 Loan facilities

7.2 Credit standby arrangements

7.3 Other (please specify)

7.4 **Total financing facilities**

Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000

7.5 **Unused financing facilities available at quarter end**

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (Item 1.9)	(2,130)
8.2 Cash and cash equivalents at quarter end (Item 4.6)	28,230
8.3 Unused finance facilities available at quarter end (Item 7.5)	-
8.4 Total available funding (Item 8.2 + Item 8.3)	28,230
8.5 Estimated quarters of funding available (Item 8.4 divided by Item 8.1)	13.2

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 21 October 2025

Authorised by: Board of Directors

(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.